Litcius/Paper detail

Choice Is Good at Times: The Emergence of [<sup>64</sup>Cu]Cu-DOTATATE–Based Somatostatin Receptor Imaging in the Era of [<sup>68</sup>Ga]Ga-DOTATATE

Abhishek Jha, Mayank Patel, Jorge A. Carrasquillo, Clara Chen, Corina Millo, Roberto Maass‐Moreno, Alexander Ling, Frank I. Lin, Ronald M. Lechan, Thomas A. Hope, David Taïeb, A. Cahid Civelek, Karel Pacák

2022Journal of Nuclear Medicine38 citationsDOIOpen Access PDF

Abstract

Somatostatin receptor (SSTR) imaging has brought about impactful changes in clinical management of neuroendocrine tumors (NETs), including pheochromocytoma and paraganglioma (PPGL) ([ 1 ][1] , [ 2 ][2]). It allows tumor detection and disease characterization and is mandatory for selecting patients

Topics & Concepts

Somatostatin receptorNeuroendocrine tumorsPheochromocytomaSomatostatinParagangliomaMedicineEndocrinologyInternal medicineCancer researchChemistryNuclear medicinePathologyNeuroendocrine Tumor Research AdvancesAdrenal and Paraganglionic TumorsNeuroblastoma Research and Treatments
Choice Is Good at Times: The Emergence of [<sup>64</sup>Cu]Cu-DOTATATE–Based Somatostatin Receptor Imaging in the Era of [<sup>68</sup>Ga]Ga-DOTATATE | Litcius